Early Access — free while we kick the tires
EdgarHawk

Kaplan Matthew L.

Director

Director
1 filing analyzed · 1 company · Latest 2025-11-06

Never miss a filing from Kaplan Matthew L.

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
Nuvectis Pharma, Inc. NVCT 1 0 Net buying

Activity

November 2025
2025-11-06 Nuvectis Pharma, Inc. NVCT
high
Buy
11,000 shares
$64,240
Significance 7/10

Director Kaplan Matthew L. buys 11,000 NVCT shares at $5.84; 3 insiders bought in past 14 days, stock down 48.4% from 52-week high, company unprofitable.

Director Kaplan Matthew L. purchased 11,000 shares at $5.84, expanding his stake by 9.7% to 124,760 shares post-transaction. This buy occurs alongside a cluster of 3 other insider purchases within the past 14 days, suggesting coordinated confidence at current levels. However, the purchase follows a significant decline: the stock trades at $5.67 versus a 52-week high of $10.98 (down 48.4%), and the company reported a full-year net loss of $-7,462,000.00, underscoring fundamental weakness. The timing of multiple insider buys against an unprofitable business in a steep drawdown warrants examination of whether this signals conviction in a turnaround or reflects contrarian positioning in a distressed situation.

Related insiders